Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Nitric Oxide  COVID-19 treatment studies for Nitric Oxide  C19 studies: Nitric Oxide  Nitric Oxide   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -54% Improvement Relative Risk Ventilation -27% Chandel et al. Nitric Oxide for COVID-19 LATE Is late treatment with nitric oxide beneficial for COVID-19? Retrospective 272 patients in the USA (March - June 2020) Higher mortality (p=0.25) and ventilation (p=0.26), not stat. sig. Chandel et al., Clinical Medicine Insights: Circ.., doi:10.1177/11795484211047065 Favors nitric oxide Favors control
Inhaled Nitric Oxide via High-Flow Nasal Cannula in Patients with Acute Respiratory Failure Related to COVID-19
Chandel et al., Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, doi:10.1177/11795484211047065
Chandel et al., Inhaled Nitric Oxide via High-Flow Nasal Cannula in Patients with Acute Respiratory Failure Related to.., Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, doi:10.1177/11795484211047065
Jan 2021   Source   PDF  
  All Studies   Meta
Retrospective 272 acute respitory failure patients in the USA treated with high-flow nasal cannula, 66 treated with inhaled nitric oxide, showing increased mortality with inhaled nitric oxide. There were significant differences in the usage of several other treatments between the groups.
risk of death, 54.1% higher, RR 1.54, p = 0.25, treatment 12 of 66 (18.2%), control 36 of 206 (17.5%), adjusted per study, odds ratio converted to relative risk, multivariable.
risk of mechanical ventilation, 27.2% higher, RR 1.27, p = 0.26, treatment 29 of 66 (43.9%), control 79 of 206 (38.3%), adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chandel et al., 31 Jan 2021, retrospective, USA, peer-reviewed, 14 authors, study period 1 March, 2020 - 9 June, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperNitric OxideAll
Inhaled Nitric Oxide via High-Flow Nasal Cannula in Patients with Acute Respiratory Failure Related to COVID-19
Abhimanyu Chandel, Saloni Patolia, Kareem Ahmad, Shambhu Aryal, A Whitney Brown, Dhwani Sahjwani, Vikramjit Khangoora, Oksana A Shlobin, Paula C Cameron, Anju Singhal, Arthur W Holtzclaw, Mehul Desai, Steven D Nathan, Christopher S King
Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, doi:10.1177/11795484211047065
INTRODUCTION: Limited evidence exists regarding use of inhaled nitric oxide (iNO) in spontaneously breathing patients. We evaluated the effectiveness of continuous iNO via high-flow nasal cannula (HFNC) in COVID-19 respiratory failure. METHODS: We performed a multicenter cohort study of patients with respiratory failure from COVID-19 managed with HFNC. Patients were stratified by administration of iNO via HFNC. Regression analysis was used to compare the need for mechanical ventilation and secondary endpoints including hospital mortality, length of stay, acute kidney injury, need for renal replacement therapy, and need for extracorporeal life support. RESULTS: A total of 272 patients were identified and 66 (24.3%) of these patients received iNO via HFNC for a median of 88 h (interquartile range: 44, 135). After 12 h of iNO, supplemental oxygen requirement was unchanged or increased in 52.7% of patients. Twenty-nine (43.9%) patients treated with iNO compared to 79 (38.3%) patients without iNO therapy required endotracheal intubation (P = .47). After multivariable adjustment, there was no difference in need for mechanical ventilation between groups (odds ratio: 1.53; 95% confidence interval [CI]: 0.74-3.17), however, iNO administration was associated with longer hospital length of stay (incidence rate ratio: 1.41; 95% CI: 1.31-1.51). No difference was found for mortality, acute kidney injury, need for renal replacement therapy, or need for extracorporeal life support. CONCLUSION: In patients with COVID-19 respiratory failure, iNO delivered via HFNC did not reduce oxygen requirements in the majority of patients or improve clinical outcomes. Given the observed association with increased length of stay, judicious selection of those likely to benefit from this therapy is warranted.
Author Contributions AC and CSK are the guarantors of the content of the manuscript and contributed to all aspects of the project. SP, KA, SA, AWB, DS, VK, OAS, AS, AWH, MD, and SDN contributed substantially to project design, data collection, and ORCID iD Abhimanyu Chandel
Abou-Arab, Huette, Debouvries, Inhaled nitric oxide for critically ill Covid-19 patients: a prospective study, Crit Care, doi:10.1186/s13054-020-03371-x
Adhikari, Dellinger, Lundin, Inhaled nitric oxide does not reduce mortality in patients with acute respiratory distress syndrome regardless of severity: systematic review and meta-analysis, Crit Care Med, doi:10.1097/CCM.0b013e3182a27909
Akerstrom, Mousavi-Jazi, Klingstrom, Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus, J Virol, doi:10.1128/JVI.79.3.1966-1969.2005
Bagate, Tuffet, Masi, Rescue therapy with inhaled nitric oxide and almitrine in COVID-19 patients with severe acute respiratory distress syndrome, Ann Intensive Care, doi:10.1186/s13613-020-00769-2
Berger, Kunichoff, Adhikari, Prevalence and outcomes of D-dimer elevation in hospitalized patients with COVID-19, Arterioscler Thromb Vasc Biol, doi:10.1161/ATVBAHA.120.314872
Chandel, Patolia, Brown, High-flow nasal cannula in COVID-19: outcomes of application and examination of the ROX index to predict success, Respir Care, doi:10.4187/respcare.08631
Chang, Elhusseiny, Yeh, COVID-19 ICU and mechanical ventilation patient characteristics and outcomes-A systematic review and meta-analysis, PLoS ONE, doi:10.1371/journal.pone.0246318
Davis, Crow, Fan, Use and costs of inhaled nitric oxide and inhaled epoprostenol in adult critically ill patients: a quality improvement project, Am J Health Syst Pharm, doi:10.1093/ajhp/zxz151
Dellinger, Zimmerman, Taylor, Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled nitric oxide in ARDS study group, Crit Care Med, doi:10.1097/00003246-199801000-00011
Demoule, Baron, Darmon, High-flow nasal cannula in critically III patients with severe COVID-19, Am J Respir Crit Care Med, doi:10.1164/rccm.202005-2007LE
Ely, Shintani, Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS), JAMA, doi:10.1001/jama.289.22.2983
Fang, Jiang, Su, The role of NO in COVID-19 and potential therapeutic strategies, Free Radic Biol Med, doi:10.1016/j.freeradbiomed.2020.12.008
Ferrari, Santini, Protti, Inhaled nitric oxide in mechanically ventilated patients with COVID-19, J Crit Care, doi:10.1016/j.jcrc.2020.08.007
Gattinoni, Coppola, Cressoni, COVID-19 does not lead to a "typical" acute respiratory distress syndrome, Am J Respir Crit Care Med, doi:10.1164/rccm.202003-0817LE
Gebistorf, Karam, Wetterslev, Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults, Cochrane Database Syst Rev, doi:10.1002/14651858.CD002787.pub3
Griffiths, Evans, Inhaled nitric oxide therapy in adults, N Engl J Med, doi:10.1056/NEJMra051884
Kline, Puskarich, Jones, Inhaled nitric oxide to treat intermediate risk pulmonary embolism: a multicenter randomized controlled trial, Nitric Oxide, doi:10.1016/j.niox.2019.01.006
Lang, Som, Mendoza, Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT, Lancet Infect Dis, doi:10.1016/s1473-3099(20)30367-4
Longobardo, Montanari, Shulman, Inhaled nitric oxide minimally improves oxygenation in COVID-19 related acute respiratory distress syndrome, Br J Anaesth, doi:10.1016/j.bja.2020.10.011
Nishimura, High-flow nasal cannula oxygen therapy in adults: physiological benefits, indication, clinical benefits, and adverse effects, Respir Care, doi:10.4187/respcare.04577
Parikh, Wilson, Weinberg, Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients, Ther Adv Respir Dis, doi:10.1177/1753466620933510
Reynolds, Lee, Renz, Pulmonary vascular dilatation detected by automated transcranial Doppler in COVID-19 pneumonia, Am J Respir Crit Care Med, doi:10.1164/rccm.202006-2219LE
Saunders, Davis, Year in review: pharmacologic treatments for COVID-19, Respir Care, doi:10.4187/respcare.09153
Tavazzi, Pozzi, Mongodi, Inhaled nitric oxide in patients admitted to intensive care unit with COVID-19 pneumonia, Crit Care, doi:10.1186/s13054-020-03222-9
Therapeutics, Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19
Tzanetos, Housley, Barr, Implementation of an inhaled nitric oxide protocol decreases direct cost associated with its use, Respir Care, doi:10.4187/respcare.03308
Wiegand, Fakhr, Carroll, Rescue treatment with high-dose gaseous nitric oxide in spontaneously breathing patients with severe coronavirus disease 2019, Crit Care Explor, doi:10.1097/cce.0000000000000277
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop